Q2 2026 saw double-digit organic growth in revenue and EPS, driven by strong performance in biologics, GLP-1s, and HVP upgrades. Guidance for the full year was raised, with margin expansion expected as the business recovers from a cyber incident and benefits from portfolio mix shifts.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.